pioglitazone has been researched along with Cronkhite-Canada Syndrome in 2 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Cronkhite-Canada Syndrome: A nonfamilial polyposis syndrome that is characterized by the presence of diffuse gastrointestinal polyposis, DIARRHEA, and PROTEIN-LOSING ENTEROPATHY. It was first reported by Cronkhite and Canada in 1955.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the present study, we assessed hyperlipidemia in Apc-deficient mice, model animals for human familial adenomatous polyposis, and examined the effects of pioglitazone and bezafibrate, respectively, PPARgamma and PPARalpha agonists, on both hyperlipidemia and intestinal polyposis." | 1.32 | Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. ( Itoh, M; Kitamura, T; Niho, N; Noda, T; Shoji, Y; Sugimura, T; Takahashi, M; Wakabayashi, K, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Niho, N | 2 |
| Takahashi, M | 2 |
| Kitamura, T | 1 |
| Shoji, Y | 2 |
| Itoh, M | 1 |
| Noda, T | 1 |
| Sugimura, T | 2 |
| Wakabayashi, K | 2 |
| Takeuchi, Y | 1 |
| Matsubara, S | 1 |
2 other studies available for pioglitazone and Cronkhite-Canada Syndrome
| Article | Year |
|---|---|
Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands.
Topics: Age Factors; Animals; Bezafibrate; Cholesterol; Fatty Acids, Nonesterified; Genes, APC; Hyperlipidem | 2003 |
Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR gamma ligand.
Topics: Animals; Cholesterol, LDL; Colonic Polyps; Dose-Response Relationship, Drug; Genes, APC; Hyperlipide | 2003 |